Articles tagged with Lung Cancer
Researchers at Thomas Jefferson University have developed a new real-time tracking technique that can better predict and track tumor motion during radiotherapy, sparing healthy tissue. The technique has shown to deliver higher levels of radiation to moving tumors while reducing dose to critical organs.
Researchers have successfully genotyped 344 NSCLC specimens with a median turnaround time of 31 days, enabling targeted therapy. This study's findings highlight the potential for large-scale genomic testing to transform lung cancer treatment.
Researchers found that local ablative therapy and continuation of targeted drugs can prolong disease control by up to 6.2 months in patients with EGFR mutations or ALK rearrangements. The study's findings suggest a new approach to treating NSCLC after progression, particularly for patients with oligoprogressive disease.
A study published in the Journal of Thoracic Oncology found that denosumab was associated with significantly improved overall median survival in lung cancer patients, including those with non-small-cell lung cancer and small-cell lung cancer. The treatment also showed improved survival in patients with squamous cell carcinoma.
A University of Cincinnati research team isolated and grew lung cancer stem cells in a preclinical model, offering a new avenue for investigating immunotherapy options that specifically target stem cells. This breakthrough could lead to the development of novel therapies targeting these cells and improving treatment outcomes.
A large-scale genome-wide association study found three genetic regions associated with lung cancer risk in Asian female never-smokers. The discovery provides evidence that common inherited genetic variants contribute to an increased risk of lung cancer among this population.
Researchers developed models from PLCO data to predict smoking status, finding that relapse and continued smoking are linked to demographic and tobacco-related characteristics. The models suggest variables like longer-term smokers, recent quitters, and pipe or cigar smokers are at higher risk for relapse.
A study of 1.3 million women found that quitting smoking can significantly reduce the risk of premature death, with smokers who stop before age 30 avoiding nearly all excess risk. The risks associated with smoking are substantial and increase with the amount smoked, highlighting the importance of quitting to extend life.
Researchers found that JHQG significantly prolonged survival in patients with non-small cell lung cancer (NSCLC), improved quality of life and activity capacity in IPF patients, and reduced fever in influenza patients compared to standard care and placebo.
Patients undergoing non-small cell lung cancer (NSCLC) resection who take statins may experience improved overall survival and reduced risk of recurrence. Statin use was associated with a significantly lower local recurrence rate compared to non-statin users.
A long-term study found that radiotherapy after surgery significantly improves biochemical progression-free survival and local control for high-risk prostate cancer patients. However, its effects on clinical progression-free survival and overall survival are less clear.
A study published in the Journal of Thoracic Oncology found that VeriStrat can predict response to erlotinib, but does not provide a survival benefit. The test showed a significant difference in median survival between good and poor responders, with good responders experiencing longer survival on erlotinib.
A study published in the Journal of Thoracic Oncology found that fit elderly patients with non-small cell lung cancer can benefit from salvage targeted therapy without increased toxicity. The study analyzed data from 255 patients and showed no difference in response rates or progression-free survival between age groups.
Scientists at the University of York have discovered a protein called Ciz1 that is present in lung cancers, even in early stages. A simple blood test using this protein could help diagnose lung cancer without invasive procedures.
A study analyzing the International Mesothelioma Interest Group (IMIG) staging system for malignant pleural mesothelioma (MPM) reveals areas for potential revision. The current system distinguishes among T and N categories, but qualitative T descriptors may not be applicable to clinical staging.
A variant in the NFKB1 gene has been associated with a 44% reduced risk of lung cancer, according to a new analysis of 378 patients and 450 healthy controls. The study suggests that inflammation may play a role in lung cancer development.
A phase III trial shows that crizotinib is more effective than standard chemotherapy in response rates and progression-free survival, with improved quality of life. The study compared 347 patients with previously treated ALK-positive lung cancer and found significant benefits for those on the crizotinib arm.
Several new first-in-human studies for drugs targeting a range of cancers have shown promising results, including the development of MEK-, MET- and HSP90 inhibitors as well as immunotherapeutic strategies. Studies have demonstrated significant activity in ALK-positive lung cancer resistant to crizotinib and other targeted therapies.
A post-hoc analysis of the phase III MISSION trial suggests that patients with EGFR-mutant tumors may benefit from sorafenib, which showed improved progression-free survival and disease control rates. In contrast, median overall survival was similar between treatment groups.
A blood test developed by Kansas State University researchers can accurately detect the beginning stages of breast and non-small cell lung cancer. The test works by detecting increased enzyme activity in the body, with a 95% success rate in detecting cancer in participants.
Researchers found that genetic diversity in natural killer cells contributes to lung cancer susceptibility. In mice, manipulating the immune system can significantly block tumor growth. The study suggests a key role for natural killer cells in lung cancer, potentially offering new targets for therapy.
Recent breast cancer research at ESMO 2012 emphasizes the importance of avoiding weight gain after treatment to reduce recurrence risk. Additionally, studies focus on the correlation between body mass index and prognosis, as well as lung cancer in never-smoking women, highlighting hormonal factors and high incidence of EGFR mutation.
A pilot study found that breath testing can accurately discriminate between benign and malignant pulmonary nodules. The technique, using volatile organic compounds and chemical nanoarrays, identified 53 malignant and 19 benign nodules with high accuracy.
Two new studies have identified novel genes and patterns of mutations involved in lung cancer, with significant differences found between smokers and non-smokers. These findings could lead to targeted therapies to improve survival rates and outcomes for lung cancer patients.
Researchers found that adding bavituximab to docetaxel chemotherapy improves response rates, progression-free survival, and overall survival in late-stage non-squamous, non-small cell lung cancer (NS-NSCLC) patients. The study showed a doubling of the overall response rate compared to the control arm.
A study of 168 Stage III NSCLC patients found that married women had the best three-year survival rate of 46 percent, while single men had the worst rate of 3 percent. Married patients generally had improved survival rates compared to single patients, with 33 percent vs. 10 percent.
Researchers found that standard chemotherapy with paclitaxel, carboplatin, and bevacizumab is equally effective as an experimental regimen in treating advanced non-squamous non-small cell lung cancer. The study suggests that both regimens are tolerable but have different toxicities.
A study of 14,829 Hispanic lung cancer patients from the California Cancer Registry found that foreign-born Hispanics have an even lower risk of death due to improved socio-economic factors and neighborhood conditions. This contradicts the traditional 'Hispanic paradox' by highlighting the positive impact of social factors on survival.
A recent study published in the University of Maryland Medical Center found that married lung cancer patients have a higher survival rate compared to single patients. The researchers believe that social support from spouses is a key factor contributing to improved survival rates for married lung cancer patients.
Crizotinib successfully shrinks tumors in patients with anaplastic lymphoma receptor tyrosine kinase (ALK) positive non-small cell lung cancer. The treatment showed a high overall response rate of 60% and improved median progression-free survival.
Patients with stage I non-small cell lung cancer (NSCLC) who received radiation therapy had an increased median survival of 21 months compared to 16 months. The percentage of patients not receiving treatment declined from 20 percent to 16 percent between 1999-2003 and 2004-2008.
The study found an increase in non-smokers developing lung cancer, particularly women, and a shift towards adenocarcinoma. Researchers attributed this change to improved diagnostic techniques and management of lung cancer.
A Phase I/II trial tests the safety and efficacy of PR610 in patients with advanced cancer. The study aims to deliver a targeted approach, activating the compound in tissues with low oxygen levels characteristic of many cancers.
A recent University of Colorado Cancer Center case study found a patient with ALK+ lung cancer who tested negative for the EML4-ALK fusion gene using the FDA-approved FISH assay, yet showed dramatic response to crizotinib. Next-gen sequencing revealed genetic shards that may have avoided detection by the test.
A lung cancer risk prediction model developed at the University of Liverpool has been shown to be a viable tool for selecting high-risk individuals. The model was tested in international datasets and found to be more effective than smoking duration or family history alone in predicting individuals at risk.
Recent studies suggest that colonoscopy-related factors are more predictive of colorectal cancer risk than polyp characteristics. High levels of lead exposure also pose significant health risks, even at low blood lead levels. Meanwhile, a new lung cancer screening model shows high accuracy in identifying patients who will benefit from ...
Researchers have identified an experimental drug, GSIs, that blocks Notch and prevents lung cancer growth in mice without treatment-related side effects. This discovery brings new clues for the treatment of lung cancer and is being tested in co-clinical trials.
Researchers have identified how EPHA3 gene mutations may promote lung cancer. The study found that loss of the gene diminishes its tumor-suppressive effect, potentially sparking tumor growth. The findings suggest that therapies targeting a downstream pathway may be beneficial for tumors with mutant EPHA3.
Researchers from the British Columbia Cancer Research Center analyzed lung tumors exposed to arsenic, highlighting genetic and epigenetic changes driving carcinogenesis. These findings may help prevent arsenic-related cancer in regions with low exposure levels.
Researchers are developing a multiple marker test in peripheral blood to detect lung cancer, promising an earlier diagnosis. The test discriminated between healthy donors and patients with non-small cell lung cancer (NSCLC) with high accuracy.
Scientists investigate the use of novel AKT inhibitor MK-2206 in combination with erlotinib as a second-line defense for patients with non-small cell lung cancer (NSCLC) who have developed resistance to erlotinib. A Phase II trial has shown promising initial results.
Chronic obstructive pulmonary disease (COPD) increases lung cancer risk through a novel mechanism involving long-term oxygen depletion and HIF-2a tumor growth signaling. COPD-induced signals may be susceptible to prevention or treatment with VEGFR-2 and EGFR inhibitors.
A new rehabilitation program developed by Michigan State University's Amy Hoffman uses the Nintendo Wii-Fit Plus to promote light-intensity walking and balance exercises. The program has shown excellent improvement in reducing cancer-related fatigue levels over time.
Researchers at Kaiser Permanente Southern California identified 7,112 patients with lung nodules using existing medical records. They developed an automated method that classifies nodules with 96% sensitivity and 86% specificity compared to clinician review.
Researchers at Mayo Clinic found that early-stage lung cancer cells use a biological process called epithelial-mesenchymal transition (EMT) to bypass growth controls and enable uncontrolled growth. This discovery offers new clues for a potential approach to treating lung and possibly other cancers as early as possible.
Researchers identify microRNA-320a as a key regulator of glycolysis in tumors and unused muscles, potentially leading to new treatments for lung cancer and improving ventilator recovery. This discovery offers a significant therapeutic leap for numerous diseases and health conditions.
Researchers at UCSF have discovered that a human protein called AXL drives resistance to Tarceva, which suggests that blocking the protein may prevent resistance to the cancer drug. This discovery may lead to better treatments involving precision medicines that combine Tarceva with new drugs designed to block AXL.
Researchers discovered that combining EGFR inhibitors with Wnt pathway inhibition can improve the durability of lung cancer remission. The Wnt pathway allows lung cancer cells to escape from EGFR-targeted therapy, but disrupting this pathway could lengthen the usefulness of existing treatments.
A new study reveals dramatic differences in lung cancer death rates among women born between 1930s and 1970s in various US states. California shows a decline in lung cancer death rates, while many southern states experience an increase, highlighting the need for stronger tobacco control policies.
Researchers are enrolling patients to detect lung cancer through volatile organic compounds in exhaled breath. Early detection can significantly improve treatment options and survival rates.
The American Association for Thoracic Surgery task force recommends expanded lung cancer screening guidelines using low-dose computed tomography (LDCT) for high-risk individuals. The new guidelines increase the recommended age range to 79 and expand eligibility to smokers and former smokers with specific risk factors.
A study published in the Journal of Thoracic Oncology found that stereotactic ablative radiotherapy is an effective treatment option for elderly patients with stage I non-small cell lung cancer. The treatment did not negatively impact health-related quality of life, and functional and symptom outcomes remained stable after two years.
A study published by the International Association for the Study of Lung Cancer found that high-volume hospitals and thoracic surgeons have lower mortality rates compared to general surgeons. The researchers recommend a national audit program to evaluate institutions based on quality parameters, including hospital volume.
Researchers discovered a new mechanism that promotes lung cancer growth and survival by regulating autophagy, a complex process initiated under stressful conditions. The protein BI-1 was found to protect lung cancer cells and suppress tumor growth by modulating intracellular signals.
Researchers found that perioperative chemotherapy improved overall survival in patients with limited large cell neuroendocrine tumors or small-cell lung cancer after surgery. The study of 74 patients showed a significant difference in overall survival between those who received chemotherapy and those who did not.
Researchers at UNC Health Care identify a key genetic switch that determines melanoma's ability to spread. Inactivating the LKB1 gene causes non-aggressive cells to become highly metastatic.
Researchers discovered that ADAM28 inhibits VWF-mediated apoptosis in cancer cells, leading to increased lung metastases. Inhibition of ADAM28 expression or activity significantly reduced lung metastases and increased cancer cell apoptosis.
LDK378 shows encouraging activity in patients with ALK+ non-small cell lung cancer, including those who no longer respond to crizotinib. The compound is well-tolerated and its optimal dose is being further tested.
A novel compound has shown significant benefits in patients with KRAS-mutant non-small cell lung cancer, improving treatment response and survival times. The study's findings suggest a potential effective treatment for this common subtype of lung cancer.
Researchers created a new anti-cancer drug named BP-1-102 that targets the Stat3 protein, which triggers cancer development in various types. The drug remains effective even when administered orally, unlike most current treatments requiring intravenous injection.